Catalog No.S1415 Synonyms: SR-25990C
Molecular Weight(MW): 419.9
Clopidogrel is an oral, thienopyridine class antiplatelet agent.
Purity & Quality Control
Choose Selective P2 Receptor Inhibitors
|Description||Clopidogrel is an oral, thienopyridine class antiplatelet agent.|
Clopidogrel is converted to its active metabolite by cytochrome P450 (CYP) enzymes.  Clopidogrel (1 μM) also inhibits EGF-stimulated EGF receptor, PERK expression, and cell proliferation in RGM-1 cells (P<0.05), and causes much less inhibition of EGF-stimulated cell proliferation in EGF receptor over-expressed RGM-1 cells than in RGM-1 cells (22% vs. 32% reduction).  Clopidogrel increases blood vessel number, reduces polymorphonuclear count and decreases attachment and bone loss, also decreases osteoclast number in rats submitted or not to periodontal repair. Clopidogrel decreases CXCL4, CXCL12 and PDGF content compared with saline-treated rats, without affecting CXCL5. 
|In vivo||Clopidogrel (2mg and 10mg/kg/day) significantly decreases ulcer-induced gastric epithelial cell proliferation and ulcer-stimulated expressions of EGF receptor and phosphorylated extracellular signal-regulated kinase (PERK) at the ulcer margin of rats.  Clopidogrel improves endothelial function and NO bioavailability in rats with congestive heart failure. Clopidogrel-treated Congestive heart failure (CHF) rat displays enhances phosphorylation of AKT and eNOS.  The clopidogrel/aspirin combination shows only additive-type effects on bleeding time prolongation induced by ear transection in the rabbit, therefore showing that combined inhibition of cyclooxygenase and ADP's effects provide a marked enhanced antithrombotic efficacy. |
-  Laine L, et al. Am J Gastroenterol, 2010, 105(1), 34-41.
-  Luo JC, et al. Eur J Pharmacol, 2012, 695(1-3), 112-119.
-  Coimbra LS, et al. J Clin Periodontol, 2014, 41(3), 295-302.
|In vitro||DMSO||83 mg/mL (197.66 mM)|
|Water||78 mg/mL (185.75 mM)|
|Ethanol||46 mg/mL (109.54 mM)|
* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT02866175||Not yet recruiting||Atrial Fibrillation||Daiichi Sankyo Inc.|European Cardiovascular Research Institute|Kompetenznetz Vorhofflimmern e.V.|Chiltern International Inc.||February 2017||Phase 3|
|NCT03023020||Not yet recruiting||High Bleeding Risk|Coronary Artery Disease|PCI||ECRI bv|Cardialysis B.V.|European Cardiovascular Research Center|University of Bern|Terumo Medical Corporation||February 2017||--|
|NCT03006835||Not yet recruiting||Coronary Heart Disease||Xijing Hospital|Shenzhen Salubris Pharmaceuticals Co., Ltd.||January 2017||Phase 4|
|NCT02663713||Recruiting||Myocardial Infarction|Diabetes Mellitus|Renal Disease|Coronary Artery Disease||University of Patras|AstraZeneca||January 2017||Phase 4|
|NCT02677545||Recruiting||Carotid Artery Stenosis||University Hospital, Basel, Switzerland||December 2016||Phase 2|
|NCT02975076||Not yet recruiting||Stroke, Acute|Ischemic Attack, Transient||Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||December 2016||--|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.